Skip to main content
Equibles

MetLife Investment Management, LLC

Position in AKTS — Aktis Oncology, Inc.

CIK 1529735 Whippany, NJ
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$418,796
+$210,611 QoQ
Shares Held
12,994
+11.7% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#66
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MetLife Investment Management, LLC holds $433,929,439 across 249 Biotechnology names. AKTS ranks #139 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 HALO
Halozyme Therapeutics, Inc.
 402,605 $31,511,893
2 PRAX
Praxis Precision Medicines, Inc.
 90,543 $30,312,890
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 58,072 $28,846,104
4 FTRE
Fortrea Holdings Inc.
 1,362,169 $23,701,740
5 AXSM
Axsome Therapeutics, Inc.
 89,662 $21,946,567
6 IMNM
Immunome Inc.
 859,076 $18,203,820
7 REGN
Regeneron Pharmaceuticals, Inc.
 22,880 $14,266,595
8 CYTK
Cytokinetics Inc
 140,046 $11,930,518

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $418,796 12,994
2026-03-31 $208,185 11,637